Targeting the Interplay of Independent Cellular Pathways and Immunity: A Challenge in Cancer Immunotherapy

被引:3
|
作者
Lauriola, Angela [1 ]
Davalli, Pierpaola [2 ]
Marverti, Gaetano [2 ]
Santi, Spartaco [3 ,4 ]
Caporali, Andrea [5 ]
D'Arca, Domenico [2 ]
机构
[1] Univ Verona, Dept Biotechnol, I-37134 Verona, Italy
[2] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, Via G Campi 287, I-41125 Modena, Italy
[3] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, I-40136 Bologna, Italy
[4] IRCCS, Ist Ortoped Rizzoli, I-40136 Bologna, Italy
[5] Univ Edinburgh, BHF Ctr Cardiovasc Sci, Edinburgh EH4 2XU, Scotland
关键词
immunotherapy; cancer; immunotherapy-challenges; immunotherapy-limitations; PROSTATE-CANCER; PHASE-II; NAB-PACLITAXEL; PATIENTS PTS; OPEN-LABEL; T-CELLS; TUMOR MICROENVIRONMENT; RECURRENT GLIOBLASTOMA; PLUS CHEMOTHERAPY; BEVACIZUMAB BEV;
D O I
10.3390/cancers15113009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy is a cancer treatment that exploits the capacity of the body's immune system to prevent, control, and remove cancer. Immunotherapy has revolutionized cancer treatment and significantly improved patient outcomes for several tumor types. However, most patients have not benefited from such therapies yet. Within the field of cancer immunotherapy, an expansion of the combination strategy that targets independent cellular pathways that can work synergistically is predicted. Here, we review some consequences of tumor cell death and increased immune system engagement in the modulation of oxidative stress and ubiquitin ligase pathways. We also indicate combinations of cancer immunotherapies and immunomodulatory targets. Additionally, we discuss imaging techniques, which are crucial for monitoring tumor responses during treatment and the immunotherapy side effects. Finally, the major outstanding questions are also presented, and directions for future research are described.
引用
收藏
页数:41
相关论文
共 50 条
  • [1] Cancer immunotherapy targeting innate immunity
    Ma, Zhifeng
    Li, Wen
    Hata, Masaki
    El-Darawish, Yosif
    Yamanishi, Kyosuke
    Yamanishi, Hiromichi
    Tanaka, Yoshimasa
    Okamura, Haruki
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S73 - S73
  • [2] IMMUNOTHERAPY AND IMMUNITY TO CANCER - CELLULAR MECHANISMS
    FERRINI, S
    MELIOLI, G
    MORETTA, L
    CURRENT OPINION IN IMMUNOLOGY, 1990, 2 (05) : 683 - 688
  • [3] Targeting inhibitory pathways in cancer immunotherapy
    Lasaro, Marcio O.
    Ertl, Hildegund C. J.
    CURRENT OPINION IN IMMUNOLOGY, 2010, 22 (03) : 385 - 390
  • [4] Editorial: Adenosine pathways in cancer immunity and immunotherapy
    Fu, Junjiang
    Antonioli, Luca
    El-Far, Ali H.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [5] Targeting innate immune pathways for cancer immunotherapy
    Cao, Longyue L.
    Kagan, Jonathan C.
    IMMUNITY, 2023, 56 (10) : 2206 - 2217
  • [6] Ferroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications
    Zhai, Xiaoqian
    Lin, Yiyun
    Zhu, Lingling
    Wang, Yuqing
    Zhang, Jiabi
    Liu, Jiewei
    Li, Lu
    Lu, Xiaojie
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 101 - 109
  • [7] Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy
    Feron, Olivier
    Chang, Chih-Hao
    Vegran, Frederique
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner
    Miao Zeng
    Wei Zhang
    Yisheng Li
    Li Yu
    Biomarker Research, 12
  • [9] Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner
    Zeng, Miao
    Zhang, Wei
    Li, Yisheng
    Yu, Li
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [10] Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
    Lukas Kraehenbuehl
    Chien-Huan Weng
    Shabnam Eghbali
    Jedd D. Wolchok
    Taha Merghoub
    Nature Reviews Clinical Oncology, 2022, 19 : 37 - 50